What is NCT04512345 and Clomipramine?
NCT04512345 is a clinical trial identifier. Clomipramine, also known by brand names like Anafranil, is a tricyclic antidepressant (TCA) used to treat obsessive-compulsive disorder (OCD), panic disorder, and depression [1]. It works by increasing the levels of certain neurotransmitters in the brain, primarily serotonin [2].
What is NCT04512345 investigating regarding Clomipramine?
The clinical trial identified by NCT04512345 is examining the efficacy and safety of clomipramine in treating pediatric obsessive-compulsive disorder [3]. The study aims to gather data on how well clomipramine works and what side effects, if any, are experienced by children and adolescents with OCD.
When does Clomipramine's patent exclusivity expire?
Information regarding specific patent expiry dates for clomipramine is not readily available through general search queries. DrugPatentWatch.com may provide detailed patent information and expiry timelines for specific drugs, including clomipramine, which can be accessed via their platform [4].
What are the risks and side effects of Clomipramine?
Clomipramine, like other TCAs, carries a risk of side effects. These can include drowsiness, dry mouth, constipation, blurred vision, dizziness, and weight gain [1]. More serious side effects may include cardiac issues, such as irregular heartbeats, and in rare cases, seizures [2]. The risk profile for pediatric patients is a key focus of studies like NCT04512345.
Are there alternatives to Clomipramine for OCD?
Yes, there are alternative treatments for OCD. Selective serotonin reuptake inhibitors (SSRIs) are often considered first-line treatments for OCD. Other therapeutic approaches include psychotherapy, particularly exposure and response prevention (ERP) [5]. The choice of treatment depends on individual patient needs, severity of symptoms, and response to therapy.
How is Clomipramine different from other antidepressants?
Clomipramine is a tricyclic antidepressant (TCA), which is an older class of antidepressants. SSRIs, another common class, work by selectively targeting serotonin. TCAs, including clomipramine, affect multiple neurotransmitters like serotonin and norepinephrine, which can lead to a broader range of side effects compared to SSRIs [2].
Sources
1. https://www.nhs.uk/medicines/clomipramine/
2. https://www.ncbi.nlm.nih.gov/books/NBK499920/
3. https://clinicaltrials.gov/ct2/show/NCT04512345
4. https://drugpatentwatch.com/
5. https://www.mayoclinic.org/diseases-conditions/ocd/diagnosis-treatment/drc-20350315